SCHEMBL3877841

SCHEMBL3877841

CC(C)(C)c1ccc(-c2ccc3c(c2)-c2ccccc2[N]3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.43
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
NR2F2 P24468 1/20 0.40
S1PR1 P21453 1/20 0.40
ALDH1A1 P00352 3/20 0.39
PLA2G1B P04054 1/20 0.39
NFKB1 P19838 1/20 0.39
CASP3 P42574 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
KDM4E B2RXH2 1/20 0.37
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961621 0.91 KIF11 (0.50) KIF11NPC1RAB9AKMT2AALDH1A1
SCHEMBL23629575 0.87 KIF11 (0.45) KIF11NPC1RAB9AKMT2AMEN1
SCHEMBL21753754 0.86 ALDH1A1 (0.52) KIF11NPC1RAB9AKMT2AMEN1
SCHEMBL2967623 0.82 MEN1 (0.47) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL3876013 0.81 MEN1 (0.40) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL22118217 0.79 RXRB (0.45) KIF11NPC1RAB9AKMT2AS1PR1
SCHEMBL20553766 0.77 ABL1 (0.50) NPC1RAB9ACASP3SENP8SENP7
SCHEMBL814080 0.76 ALDH1A1 (0.45) KIF11NPC1RAB9AKMT2AMEN1
SCHEMBL814578 0.76 MEN1 (0.47) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL20553967 0.75 ENPP3 (0.44) NPC1RAB9AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482490-B2 Amine compound having fluorene group as framework, process for producing the amine compound, and use of the amine compound TOSOH CORPORATION (JP) 2009-01-27 US disclosed
US-20080194878-A1 Amine Compound Having Fluorene Group as Framework, Process for Producing the Amine Compound, and Use of the Amine Compound TOSOH CORPORATION (JP) 2008-08-14 US disclosed
US-7189877-B2 Arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSCH CORPORATION (JP) 2007-03-13 US disclosed
EP-1752440-A1 AMINE COMPOUND HAVING FLUORENE GROUP AS FRAMEWORK, PROCESS FOR PRODUCING THE AMINE COMPOUND, AND USE OF THE AMINE COMPOUND Tosoh Corporation (JP) 2007-02-14 EP disclosed
EP-1400578-B1 Electrolumisescent 9,9-bis(4-amino)-1,1'-biphenyl)fluorene derivatives TOSOH CORP (JP) 2005-11-30 EP disclosed
US-20040110958-A1 Novel arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices TOSOH CORPORATION 2004-06-10 US disclosed
EP-1400578-A1 Electrolumisescent 9,9-bis(4-amino)-1,1'-biphenyl)fluorene derivatives Tosoh Corporation (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110958-A1 Novel arylamine derivatives having fluorene skeleton, synthetic intermediates thereof, processes of producing those, and organic electrolumivescene devices AHR, NAT1, AR KIF11 3501/4885NPC1 2320/4885RAB9A 1907/4885
US-20080194878-A1 Amine Compound Having Fluorene Group as Framework, Process for Producing the Amine Compound, and Use of the Amine Compound TAAR1, SLC18A1, ADRB2 KIF11 2692/4885NPC1 1532/4885RAB9A 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.